Evaluation of prodynorphin gene polymorphisms and their association with heroin addiction in a sample of the southeast Iranian population

Document Type : Original article

Authors

1 Cellular and Molecular Research Center, Zahedan University of Medical Sciences, Zahedan, Iran

2 Department of Clinical Biochemistry, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran

3 Department of Psychiatry, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran

4 Department of Clinical Psychology, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran

Abstract

Genetic factors are supposed to account for about 30-50% of the predisposition to cocaine and heroin addiction. This study aims at investigating the effect of rs2281285, rs2235749, rs910080 and 68bp VNTR polymorphisms of prodynorphin (PDYN) gene on heroin dependence risk in a sample of the southeast Iranian population. This case-control study was done on 216 heroin dependence subjects and 219 healthy subjects. Genomic DNA was extracted from peripheral blood cells using salting out method. Genotyping of PDYN polymorphisms were performed using polymerase chain reaction (PCR) or PCR-RFLP method. The findings showed that PDYN rs910080 T>C variant significantly increased the risk of heroin dependence (OR=7.91, 95%CI=3.36-18.61, P<0.0001, CC vs TT; OR=7.53, 95%CI=3.30-17.16, P<0.0001, CC vs TT+TC; OR=1.75, 95%CI=1.33-2.32, p<0.0001, C vs T). The rs2235749 C>T, rs2281285 A>G and 68bp VNTR variants of PDYN gene were not associated with heroin dependence. Altogether, our results provide an association between rs910080 polymorphism of PDYN gene and risk of heroin dependence in a sample of the southeast Iranian population.

Keywords

References

1. Ebrahimi G, Asadikarm G, Hashemi M. Elevated levels of DNA methylation at the OPRM1 promoter region in the male opium use disorders. J  Drug Alcohol Abuse 2017;DOI: 10.1080/00952990.2016.1275659.
2. Cami J, Farre M. Drug addiction. N Engl J Med 2003;349:975-986.
3. Kendler KS, Jacobson KC, Prescott CA, Neale MC. Specificity of genetic and environmental risk factors for use and abuse/dependence of cannabis, cocaine, hallucinogens, sedatives, stimulants, and opiates in male twins. Am J Psychiatry 2003;160:687-695.
4. Tsuang MT, Lyons MJ, Meyer JM, Doyle T, Eisen SA, Goldberg J, True W, Lin N, Toomey R, Eaves L. Co-occurrence of abuse of different drugs in men: the role of drug-specific and shared vulnerabilities. Arch Gen Psychiatry 1998;55:967-972.
5. van den Bree MB, Johnson EO, Neale MC, Pickens RW. Genetic and environmental influences on drug use and abuse/dependence in male and female twins. Drug Alcohol Depend 1998;52:231-241.
6. Litt M, Buroker NE, Kondoleon S, Douglass J, Liston D, Sheehy R, Magenis RE. Chromosomal localization of the human proenkephalin and prodynorphin genes. Am J Hum Genet 1988;42:327-334.
7. Schwarzer C. 30 years of dynorphins--new insights on their functions in neuropsychiatric diseases. Pharmacol Ther 2009;123:353-370.
8. Kosterlitz HW, Corbett AD, Paterson SJ. Opioid receptors and ligands. NIDA Res Monogr 1989;95:159-166.
9. Chavkin C, Goldstein A. Specific receptor for the opioid peptide dynorphin: structure--activity relationships. Proc Natl Acad Sci U S A 1981;78:6543-6547.
10. Margolis EB, Lock H, Chefer VI, Shippenberg TS, Hjelmstad GO, Fields HL. Kappa opioids selectively control dopaminergic neurons projecting to the prefrontal cortex. Proc Natl Acad Sci USA 2006;103:2938-2942.
11. Steiner H, Gerfen CR. Dynorphin regulates D1 dopamine receptor-mediated responses in the striatum: relative contributions of pre- and postsynaptic mechanisms in dorsal and ventral striatum demonstrated by altered immediate-early gene induction. J Comp Neurol 1996;376: 530-541.
12. Steiner H, Gerfen CR. Role of dynorphin and enkephalin in the regulation of striatal output pathways and behavior. Exp Brain Res 1998;123:60-76.
13. Preuss UW, Winham SJ, Biernacka JM, Geske JR, Bakalkin G, Koller G, Zill P, Soyka M, Karpyak VM. PDYN rs2281285 variant association with drinking to avoid emotional or somatic discomfort. PLoS One 2013;8:e78688.
14. Egervari G, Jutras-Aswad D, Landry J, Miller ML, Anderson SA, Michaelides M, Jacobs MM, Peter C, Yiannoulos G, Liu X, Hurd YL. A Functional 3'UTR polymorphism (rs2235749) of prodynorphin alters microRNA-365 binding in ventral striatonigral neurons to influence novelty seeking and positive reward traits. Neuropsychopharmacology 2016; 41:2512-2520.
15. Clarke TK, Krause K, Li T, Schumann G. An association of prodynorphin polymorphisms and opioid dependence in females in a Chinese population. Addict Biol 2009;14:366-370.
16. Flory JD, Pytte CL, Hurd Y, Ferrell RE, Manuck SB. Alcohol dependence, disinhibited behavior and variation in the prodynorphin gene. Biol Psychol 2011;88:51-56.
17. Yuferov V, Levran O, Proudnikov D, Nielsen DA, Kreek MJ. Search for genetic markers and functional variants involved in the development of opiate and cocaine addiction and treatment. Ann N Y Acad Sci 2010;1187:184-207.
18. Nikoshkov A, Drakenberg K, Wang X, Horvath MC, Keller E, Hurd YL. Opioid neuropeptide genotypes in relation to heroin abuse: dopamine tone contributes to reversed mesolimbic proenkephalin expression. Proc Natl Acad Sci USA 2008;105:786-791.
19. Ray R, Doyle GA, Crowley JJ, Buono RJ, Oslin DW, Patkar AA, Mannelli P, DeMaria PA, Jr., O'Brien CP, Berrettini WH. A functional prodynorphin promoter polymorphism and opioid dependence. Psychiatry Genet 2005;15:295-298.
20. Saify K, Saadat I, Saadat M. Association between VNTR polymorphism in promoter region of prodynorphin (PDYN) gene and heroin dependence. Psychiatry Res 2014;219:690-692.
21. Butelman ER, Yuferov V, Kreek MJ. kappa-opioid receptor/dynorphin system: genetic and pharmacotherapeutic implications for addiction. Trends Neurosci 2012;35:587-596.
22. Knoll AT, Carlezon WA, Jr. Dynorphin, stress, and depression. Brain Res 2010;1314:56-73.
23. Wee S, Koob GF. The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse. Psychopharmacology (Berl) 2010;210:121-135.
24.Sirohi S, Bakalkin G, Walker BM. Alcohol-induced plasticity in the dynorphin/kappa-opioid receptor system. Front Mol Neurosci 2012;5:95.
25. Bazov I, Kononenko O, Watanabe H, Kuntic V, Sarkisyan D, Taqi MM, Hussain MZ, Nyberg F, Yakovleva T, Bakalkin G. The endogenous opioid system in human alcoholics: molecular adaptations in brain areas involved in cognitive control of addiction. Addict Biol 2013;18:161-169.
26. Saify K, Saadat M. Association between VNTR polymorphism in promoter region of prodynorphin (PDYN) gene and methamphetamine dependence. Open Access Maced J Med Sci 2015;3:371-373.
27. Zimprich A, Kraus J, Woltje M, Mayer P, Rauch E, Hollt V. An allelic variation in the human prodynorphin gene promoter alters stimulus-induced expression. J Neurochem 2000; 74:472-477.
28. Williams TJ, LaForge KS, Gordon D, Bart G, Kellogg S, Ott J, Kreek MJ. Prodynorphin gene promoter repeat associated with cocaine/alcohol codependence. Addict Biol 2007; 12:496-502.
29. Dahl JP, Weller AE, Kampman KM, Oslin DW, Lohoff FW, Ferraro TN, O'Brien CP, Berrettini WH. Confirmation of the association between a polymorphism in the promoter region of the prodynorphin gene and cocaine dependence. Am J Med Genet B Neuropsychiatr Genet 2005;139B:106-108.
30. Rouault M, Nielsen DA, Ho A, Kreek MJ, Yuferov V. Cell-specific effects of variants of the 68-base pair tandem repeat on prodynorphin gene promoter activity. Addict Biol 2011;16: 334-346.
31. D'Addario C, Shchetynsky K, Pucci M, Cifani C, Gunnar A, Vukojevic V, Padyukov L, Terenius L. Genetic variation and epigenetic modification of the prodynorphin gene in peripheral blood cells in alcoholism. Prog Neuropsychopharmacol Biol Psychiatry 2017;76: 195-203.

Files

Share

How to cite

Statistics